← SynDRA
VANDETANIB
SynDRA canonical compound SYN0001517 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | TEK |
|---|
| Mechanism of action | RET tyrosine kinase inhibitor |
|---|
| Indication | medullary thyroid cancer (MTC) |
|---|
| Disease area | oncology |
|---|
All known targets
- KDR
- RET
- EGFR
- PTK6
- FLT4
- FLT1
- TEK
- EPHA7
- EPHA2
- EPHA3
- EPHA4
- EPHA5
Mechanisms of action (all sources)
- EGFR INHIBITOR
- VEGFR inhibitor
- RET tyrosine kinase inhibitor
- SRC inhibitor
- Tyrosine-protein kinase SRC inhibitor
- PTK6 INHIBITOR
- Tyrosine-protein kinase BRK inhibitor
- TEK INHIBITOR
- Tyrosine-protein kinase TIE-2 inhibitor
- FLT1 INHIBITOR
- Vascular endothelial growth factor receptor inhibitor
- FLT4 INHIBITOR
Drug classes
- Protein Kinase Inhibitors
- Kinase Inhibitor
- P-Glycoprotein Inhibitors
- Organic Cation Transporter 2 Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- ZD-6474
- zactima
- caprelsa
- ZD6474
- GNF-PF-2188
- NSC-744325
- NSC-760766
- ZD-64
- Caprelsa
- Zactima
- Vandetanib [INN]
- CH-331
- AZD-6474
- F9995-0087
- Zactima, ZD6474
- Vandetanib (JAN/INN)
- Vandetanib, Zactima, ZD6474
- N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine
- N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine
- N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine
- 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline
- Vandetanib (Pan-TK inhibitor)
- vandetanib (zd6474)
- ZD 6474
- NSC 744325
- NSC 760766
- CHEMBL24828
- YO460OQ37K
- CHEBI:49960
- MFCD07772346
- NCGC00167513-01
- 4-[(4-Bromo-2-fluorophenyl)amino]-6-methoxy-7-[(1-methyl-4-piperidyl)methoxy]quinazoline
- N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine
- 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-yl)methoxyquinazoline
- (4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine
- CAS-443913-73-3
- UNII-YO460OQ37K
- Vandetinib
Reported adverse events
- Torsades de pointes
- Acne
- Alopecia
- Colitis
- Depression
- Dermatitis
- Dysgeusia
- Dyspepsia
- Fatigue
- Headache
- Hypertension
- Hypothyroidism
Look up VANDETANIB in the interactive SynDRA portal →